Results 81 to 90 of about 188,812 (316)

Topical tetracaine prior to arterial puncture: a randomized, placebo-controlled clinical trial [PDF]

Respiratory Medicine, 2003
The objective of this randomized, double-blind, placebo-controlled clinical trial was to determine whether a topical anesthetic agent (tetracaine) provides effective local analgesia prior to radial arterial puncture. Tetracaine or placebo gel was applied 45 min prior to arterial puncture to patients who were referred for elective arterial blood gas ...
Aaron, Shawn D, Vandemheen, Katherine L, Naftel, Sheila A, Lewis, Mary-Jo, Rodger, Marc A   +4 more
openaire   +2 more sources

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

Treatment of acute Old World cutaneous leishmaniasis : a systematic review of the randomized controlled trials

, 2007
BACKGROUND: Cutaneous leishmaniasis (CL) is caused by different species of Leishmania and transmitted by the bite of infected sand flies. It is a health problem in many countries.OBJECTIVE: This study was performed to assess the evidence for the efficacy
Dowlati, Yahya, Gorouhi, Farzam, Khatami, Alireza, Firooz, Alireza   +3 more
core   +1 more source

USP29‐regulated noncanonical stabilization of the hypoxia‐inducible factor‐α in aggressive prostate cancer

Molecular Oncology, EarlyView.
We identify USP29 as the only DUB mirroring CA9 expression, a marker of hypoxia and HIF pathway activation associated with PCA aggressiveness. USP29 stabilizes HIF‐1α and HIF‐2α via a noncanonical mechanism that is independent of PHD/pVHL activity yet relies on proteasomal regulation, establishing USP29 as a previously unrecognized regulator of hypoxic
Amelie S Schober, Leire Moreno‐Cugnon, Laura Martínez‐Pérez, Amaia Ercilla, Amaia Zabala‐Letona, Adrián Vicente‐Barrueco, Maider Fagoaga‐Eugui, Saioa Garcia‐Longarte, Blanca Calle‐Ciborro, Encarnación Pérez‐Andrés, Onintza Carlevaris, Sara Pozo, Isabel Mendizabal, Ugo Mayor, Arkaitz Carracedo, Violaine Sée, Edurne Berra   +16 more
wiley   +1 more source

Using Randomized Controlled Trials for Treatment Decisions

, 2016
Introduction Numerous studies have demonstrated that many physicians lack fundamental skills of interpreting and using clinical care evidence. Building a foundation for evidence-based medicine (EBM) will provide an initial scaffold that can be integrated
Gerald Crites, Laurel Murrow, W. Scott Richardson, Jennifer Stowe, Julie Gaines   +4 more
core   +1 more source

Methods to increase response to postal and electronic questionnaires [PDF]

, 2009
Background: Postal and electronic questionnaires are widely used for data collection in epidemiological studies but non-response reduces the effective sample size and can introduce bias.
Mike J Clarke, Edwards, Philip James, Carolyn DiGuiseppi, Sarah Pratap, Rachel Cooper, Clarke, Mike J, Diguiseppi, Carolyn, Roberts, I., Felix, L.M., Clarke, Mike J., Kwan, I., Wentz, R., Lambert M Felix, DiGuiseppi, C., Kwan, Irene, Cooper, R., Clarke, Mike; id_orcid, Reinhard Wentz, Pratap, S., Pratap, Sarah, Irene Kwan, Roberts, Ian, Philip James Edwards, Felix, Lambert M., Ian Roberts, Wentz, Reinhard, Felix, Lambert M, Cooper, Rachel, Edwards, P.J.   +28 more
core   +1 more source

Effect of consuming food cooked in iron pots and behavior change communication on iron status in non-pregnant, non-lactating women: protocol for randomized controlled trial

Trials
Background Iron-deficiency anemia (IDA) remains a significant public health concern, particularly among women of reproductive age in developing countries.
Umesh Kawalkar, Shital Telrandhe, Mahalaqua Nazli Khatib, Shilpa Gaidhane, Zahiruddin Quazi Syed, Amar Mankar, Abhay Gaidhane   +6 more
doaj   +1 more source

Topical herbal medicines for atopic eczema: a systematic review of randomized controlled trials [PDF]

British Journal of Dermatology, 2016
Despite the availability of medicines with proven efficacy, many patients use complementary or alternative medicines (CAMs) to manage atopic eczema (AE). Due to the lack of objective information on topical CAMs, this systematic review evaluates the current evidence for the efficacy and safety of topical herbal preparations in AE.
Thandar, Yasmeen, Gray, A., Botha, Julia, Mosam, Anisa   +3 more
openaire   +3 more sources